New Product Launch BIOPONIB®ponatinib

26/04/2023

Bioprofarma Bagó is pleased to present the launch of BIOPONIB® ponatinib for its Hematology Business Unit.

BIOPONIB® ponatinib is approved by ANMAT for the treatment of Chronic Myeloid Leukemia (CML) and Philadelphia chromosome positive Acute Lymphoblastic Leukemia (Ph+ ALL) in adult patients who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and in whom subsequent treatment with imatinib is not clinically indicated; or who present the T315I mutation.

HOW SUPPLIED:

BIOPONIB® 15 mg x 30 coated tablets
BIOPONIB® 15 mg x 60 coated tablets
BIOPONIB® 45 mg x 60 coated tablets

BIOPONIB® ponatinib joins the portfolio of products for the treatment of CML and ALL PH+, together with CLINID®imatinib and DAPIBUS® dasatinib.

This new treatment alternative comes to provide specialists with more options for the care of their patients.

XXVI Argentine and International Congress of Clinical Oncology organized by the AAOC

November 8-10, the XXVI Argentine and International Congress of Clinical Oncology 2023 was held at La Rural, in the City of Buenos Aires, and Bioprofarma Bago was there.

Read note

26th ARGENTINE CONGRESS OF HEMATOLOGY organized by the Argentine Society of Hematology

Bioprofarma Bagó participated in the 26th Argentine Congress of Hematology 2023, which was held from November 1st to the 4th at its two venues: the Sheraton Hotel and the Costa Galana Hotel, in the City of Mar del Plata.

Read note

New Product Launch VETRANO®palbociclib

We are thrilled to present to our community the launch of the product VETRANO® palbociclib, for our Oncology Line.

Read note